Departamento de Biología Molecular, Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, Granada, Spain.
Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, La Laguna, Spain.
Front Cell Infect Microbiol. 2024 Jul 23;14:1439714. doi: 10.3389/fcimb.2024.1439714. eCollection 2024.
Chagas disease, caused by the parasite infection, is a potentially life-threatening neglected tropical disease with a worldwide distribution. During the chronic phase of the disease, there exists a fragile balance between the host immune response and parasite replication that keeps patients in a clinically-silent asymptomatic stage for years or even decades. However, in 40% of patients, the disease progresses to clinical manifestations mainly affecting and compromising the cardiac system. Treatment is recommended in the chronic phase, although there are no early markers of its effectiveness. The aim of this study is to identify differential expression changes in genes involved in the immune response in antigen-restimulated PBMC from chronic patients with Chagas disease due to benznidazole treatment.
Thus, high-throughput real-time qPCR analysis has been performed to simultaneously determine global changes in the expression of 106 genes involved in the immune response in asymptomatic (IND) and early cardiac manifestations (CCC I) Chagas disease patients pre- and post-treatment with benznidazole.
The results revealed that 7 out of the 106 analyzed genes were differentially expressed (4 up- and 3 downregulated) after treatment in IND patients and 15 out of 106 (3 up- and 12 downregulated) after treatment of early cardiac Chagas disease patients. Particularly in CCC I patients, regulation of the expression level of some of these genes towards a level similar to that of healthy subjects suggests a beneficial effect of treatment and supports recommendation of benznidazole administration to early cardiac Chagas disease patients. The data obtained also demonstrated that both in asymptomatic patients and in early cardiac chronic patients, after treatment with benznidazole there is a negative regulation of the proinflammatory and cytotoxic responses triggered as a consequence of infection and the persistence of the parasite. This downregulation of the immune response likely prevents marked tissue damage and healing in early cardiac patients, suggesting its positive effect in controlling the pathology.
恰加斯病是由寄生虫感染引起的一种潜在危及生命的被忽视的热带病,在全球范围内广泛分布。在疾病的慢性期,宿主免疫反应和寄生虫复制之间存在脆弱的平衡,使患者多年甚至几十年处于临床无症状的无症状期。然而,在 40%的患者中,疾病会进展为主要影响和损害心脏系统的临床表现。尽管没有其疗效的早期标志物,但建议在慢性期进行治疗。本研究的目的是确定因苯并咪唑治疗而导致的慢性恰加斯病患者抗原刺激的 PBMC 中参与免疫反应的基因的差异表达变化。
因此,进行了高通量实时 qPCR 分析,以同时确定无症状(IND)和早期心脏表现(CCC I)恰加斯病患者在接受苯并咪唑治疗前后,106 个参与免疫反应的基因的表达的全局变化。
结果表明,在 IND 患者治疗后有 7 个(4 个上调和 3 个下调)和 15 个(3 个上调和 12 个下调)分析基因在早期心脏恰加斯病患者治疗后表达差异。特别是在 CCC I 患者中,这些基因的一些表达水平的调节向与健康受试者相似的水平表明治疗的有益效果,并支持建议对早期心脏恰加斯病患者使用苯并咪唑。获得的数据还表明,在无症状患者和早期心脏慢性患者中,在接受苯并咪唑治疗后,感染引起的促炎和细胞毒性反应以及寄生虫的持续存在会受到负调节。这种免疫反应的下调可能防止了早期心脏患者明显的组织损伤和愈合,表明其在控制病理学方面的积极作用。